Table 1 Demographic and clinical characteristics of the subjects according to dexamethasone
Control (n = 19) | Dexamethasone(n = 19) | |
|---|---|---|
Demographics | ||
Age (years) | 65.60 ± 7.94 | 66.50 ± 8.44 |
Female sex | 5 (26.3) | 6 (31.6) |
Body mass index (kg/m2) | 24.20 ± 2.44 | 24.54 ± 2.48 |
ASA class | ||
I | 5 | 2 |
II | 14 | 17 |
Legion location | ||
Right upper lobe | 6 | 6 |
Right middle lobe | 2 | 1 |
Right lower lobe | 5 | 6 |
Left upper lobe | 1 | 2 |
Left lower lobe | 5 | 4 |
Laboratory data | ||
Hematocrit (%) | 39.23 ± 2.77 | 38.63 ± 2.92 |
Creatinine (mg/dL) | 0.74 [0.64–0.84] | 0.76 [0.67–0.98] |
Albumin (g/dL) | 3.80 [3.70–3.98] | 3.85 [3.33–4.20] |
C-reactive protein (mg/dL) | 0.20 [0.10–1.78] | 0.52 [0.11–1.48] |
Glucose (mg/dL) | 115 [107–142] | 126 [106–156] |
Sodium (mmol/L) | 140 [137–142] | 140 [137–142] |
Potassium (mmol/L) | 4.25 ± 0.21 | 4.29 ± 0.36 |
Pulmonary function test | ||
FVC (% predicted) | 93.06 ± 16.07 | 85.19 ± 11.48 |
FEV1 (% predicted) | 88.72 ± 20.31 | 81.52 ± 16.99 |
FEV1/FVC | 69.05 ± 11.42 | 68.55 ± 10.60 |
Medical history | ||
Diabetes mellitus | 3 (15.79) | 5 (26.32) |
Hypertension | 5 (26.32) | 6 (31.58) |
Dyslipidemia | 3 (15.79) | 4 (21.05) |
Smoker, current | 5 (26.32) | 4 (21.05) |
Intraoperative data | ||
Anesthetic agent | ||
Propofol (mg) | 1084.5 ± 301.4 | 1157.8 ± 390.4 |
Remifentanil (μg) | 5530.4 ± 1879.1 | 6428.0 ± 3616.3 |
Anesthetic time (min) | 237.5 [211.3–301.3] | 257.5 [230.0–322.5] |
Operation time (min) | 165.0 [145.0–236.5] | 192.5 [165.0–251.3] |
Intraoperative infused volume | ||
Crystalloid (L) | 1.0 [0.8–1.6] | 1.1 [0.8–1.4] |
Colloid (L) | 0.6 [0–1.0] | 0.6 [0.4–1.0] |
Urine output (mL) | 207.5 [132.5–377.5] | 240.0 [112.5–802.5] |
Use of vasopressor, n | 12 (63.16) | 11 (57.90) |